TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

Key facts

Sponsor

Centers for Disease Control and Prevention

Principal Investigator

Richard E Chaisson, MD

Johns Hopkins University

Intervention

Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)(drug)

Enrollment

433 enrolled

Eligibility

18 years · All sexes

Timeline

2006 – 2007

Study locations (26)

• Veterans Administration Medical Center of Arkansas, Little Rock, Arkansas, United States
• University of Southern California Medical Center, Los Angeles, California, United States
• University of California at San Diego, San Diego, California, United States
• University of California, San Francincisco, San Francisco, California, United States
• Denver Public Health Department, Denver, Colorado, United States
• Washington DC Veterans Administration Medical Center, Washington D.C., District of Columbia, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• Northwestern University, Chicago, Illinois, United States
• Hines Veterans Administration Medical Center, Hines, Illinois, United States
• Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
• Boston University Medical Center, Boston, Massachusetts, United States
• New Jersey School of Medicine, Newark, New Jersey, United States
• Columbia University, New York, New York, United States
• Harlem Hospital, Columbia University, New York, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• +11 more locations on ClinicalTrials.gov

Collaborators

Global Alliance for TB Drug Development · Bayer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07164742
  Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
  Johns Hopkins University
• RECRUITINGNCT07077213
  18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
  Children's Hospital Medical Center, Cincinnati
• ENROLLING BY INVITATIONNANCT06984887
  Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
  Mercy Corps Pakistan
• RECRUITINGNCT07018076
  Candidate Clinical Correlate of Prognostic Outcome for TB Study
  University of California, San Francisco
• RECRUITINGNANCT07271225
  Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
  Indonesia University
• RECRUITINGNCT06585358
  DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
  Karolinska Institutet
• RECRUITINGPHASE3NCT06497465
  Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
  Johns Hopkins University
• RECRUITINGNCT07178860
  Respiratory Health and Wellbeing Post Pulmonary Tuberculosis
  Liverpool School of Tropical Medicine

See all trials for Tuberculosis →